ATE265448T1 - Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung - Google Patents

Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung

Info

Publication number
ATE265448T1
ATE265448T1 AT00957317T AT00957317T ATE265448T1 AT E265448 T1 ATE265448 T1 AT E265448T1 AT 00957317 T AT00957317 T AT 00957317T AT 00957317 T AT00957317 T AT 00957317T AT E265448 T1 ATE265448 T1 AT E265448T1
Authority
AT
Austria
Prior art keywords
pyridazine
condensated
inhibiting action
substituted
angiogenesis inhibiting
Prior art date
Application number
AT00957317T
Other languages
English (en)
Inventor
Jacques P Dumas
Holia N Hatoum-Mokdad
Teddy Kite Joe
Harold C E Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N Sibley
Ning Su
Stephen James Boyer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of ATE265448T1 publication Critical patent/ATE265448T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT00957317T 1999-08-10 2000-08-08 Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung ATE265448T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37132299A 1999-08-10 1999-08-10
PCT/US2000/021579 WO2001010859A1 (en) 1999-08-10 2000-08-08 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Publications (1)

Publication Number Publication Date
ATE265448T1 true ATE265448T1 (de) 2004-05-15

Family

ID=23463486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957317T ATE265448T1 (de) 1999-08-10 2000-08-08 Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung

Country Status (19)

Country Link
EP (1) EP1208096B1 (de)
JP (1) JP2003506447A (de)
KR (1) KR20020019969A (de)
CN (1) CN1378543A (de)
AR (1) AR025068A1 (de)
AT (1) ATE265448T1 (de)
AU (1) AU775237B2 (de)
BR (1) BR0013113A (de)
CA (1) CA2381621A1 (de)
CO (1) CO5180637A1 (de)
DE (1) DE60010280T2 (de)
ES (1) ES2219382T3 (de)
IL (1) IL147885A0 (de)
MX (1) MXPA02001324A (de)
NO (1) NO20020569L (de)
NZ (1) NZ517087A (de)
PE (1) PE20010494A1 (de)
WO (1) WO2001010859A1 (de)
ZA (1) ZA200200691B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
SI1427420T1 (sl) * 2001-09-12 2006-12-31 Novartis Ag Uporaba kombinacije, ki vsebuje 4-piridilmetilftalazine za zdravljenje raka
AU2002364102A1 (en) * 2001-12-21 2003-07-30 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003299065B2 (en) * 2002-09-24 2006-10-26 Novartis Ag Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
US20060058313A1 (en) * 2002-11-12 2006-03-16 Hohneker John A Treatment of mesothelioma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
ES2395877T3 (es) 2007-06-19 2013-02-15 Rynel, Inc. Materiales que comprenden partículas poliméricas solubles en agua y métodos para prepararlos y usarlos
MX2010010151A (es) 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
AU2009279760B2 (en) * 2008-08-04 2012-07-12 Amgen Inc. Aurora kinase modulators and methods of use
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
JPH0673022A (ja) * 1992-08-27 1994-03-15 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
ES2224130T3 (es) * 1994-08-09 2005-03-01 Eisai Co., Ltd. Compuesto de piridazina condensada.
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
BR0009507A (pt) * 1999-03-30 2002-01-15 Novartis Ag Derivados de ftalazina para o tratamento de doenças inflamatórias

Also Published As

Publication number Publication date
AU6895400A (en) 2001-03-05
NO20020569L (no) 2002-04-10
DE60010280T2 (de) 2009-10-15
EP1208096B1 (de) 2004-04-28
CO5180637A1 (es) 2002-07-30
EP1208096A1 (de) 2002-05-29
JP2003506447A (ja) 2003-02-18
DE60010280D1 (de) 2004-06-03
KR20020019969A (ko) 2002-03-13
ZA200200691B (en) 2003-10-29
WO2001010859A1 (en) 2001-02-15
AR025068A1 (es) 2002-11-06
CA2381621A1 (en) 2001-02-15
NZ517087A (en) 2004-05-28
BR0013113A (pt) 2002-04-30
CN1378543A (zh) 2002-11-06
AU775237B2 (en) 2004-07-22
MXPA02001324A (es) 2002-07-22
IL147885A0 (en) 2002-08-14
ES2219382T3 (es) 2004-12-01
NO20020569D0 (no) 2002-02-05
PE20010494A1 (es) 2001-06-27

Similar Documents

Publication Publication Date Title
DE69826841D1 (de) Phthalazines mit angiogenesis-hemmender wirkung
DE60012213D1 (de) Fünfgliedrige n-heterocyclen mit hypoglykämischer und hypolipidemischer wirkung
ATE265448T1 (de) Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung
DE60039065D1 (de) Mehrkeulenantenne
NO20002822D0 (no) Termisk kretskontakt og bryter
DE60102555D1 (de) Verhinderung der map-aktivierten modulmaskeradeangriffe
ATE422494T1 (de) Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung
ATE243885T1 (de) Schaltschutz
DE60036005D1 (de) Riegel
PT1139761E (pt) Composicoes herbicidas e concentrados tensioactivos
NO20015744D0 (no) Bredspektrede antimikrobielle blandinger
DE50006919D1 (de) Femurschlitten
DE60023454D1 (de) Lagenmaterialen mit tensid-modifizierten chelatbildern behandelt
DE60003873D1 (de) Resistzusammensetzungen und Strukturierungsverfahren
DE60025700D1 (de) Polyester formmasse
DE60027819D1 (de) Elektromagnetischer mehrpoliger Schalter
DE69820186D1 (de) Gegen heisse Elektronen geschützte Schaltung und Methode
NO20002823D0 (no) Termisk kretskontakt og bryter
DE69914317D1 (de) Polyesterzusammensetzungen
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
DE69931468D1 (de) Elektromagnetischer schütz
DE69614995T2 (de) Rücksetzverriegelungsschaltung
FR2797989B1 (fr) Disjoncteur
NO20004568L (no) Forbrenningsovn
ATE365723T1 (de) Il-5 hemmende 6-uracilderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties